[1]
|
www.wikipedia.org/wiki/Bosentan.
|
[2]
|
www.drugbank.ca/drugs/DB00559.
|
[3]
|
www.chemblink.com/products/147536-97-8.htm.
|
[4]
|
B. Lausecker, B. Hess, G. Fischer, M. Mueller and G. Hopfgartner, “Simultaneous Determination of Bosentan and Its Three Major Metabolites in Various Biological Matrices and Species Using Narrow Bore Liquid Chromatography with Ion Spray Tandem Mass Spectrometric Detection,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 749, No. 1, 2000, pp. 67- 83. doi:10.1016/S0378-4347(00)00386-8
|
[5]
|
A. S. Jadhav, B. S. Landge, S. L. Jadhav, N. C. Niphade, S. R. Bembalkar and V. T. Mathad, “Stability-Indicating Gradient RP-LC Method for the Determination of Process and Degradation Impurities in Bosentan Monohydrate: An Endothelin Receptor Antagonist,” Chromatography Research International, Vol. 2011, 2011.
|
[6]
|
M. M. Annapurna, S. P. S. Bisht, B. V. V. R. Kumar, V. R. Kumar and A. Narendra, “Spectrophotometric Determination of Bosentan and Its Application in Pharmaceutical Analysis,” International Journal of Comprehensive Pharmacy, Vol. 2, No. 2, 2011.
|
[7]
|
M. A. Gatzoulis, M. Beghetti, N. Galiè, J. Granton, R. M. F. Berger, A. Lauer, E. Chiossi and M. Landzberg, “Longer-Term Bosentan Therapy Improves Functional Capacity in Eisenmenger Syndrome: Results of the BREATHE-5 Open-Label Extension Study,” International Journal of Cardiology, Vol. 27, No. 1, 2008, pp. 27-32.
|
[8]
|
J. M. Parekh, D. K. Shah, M. Sanyal, M. Yadav and P. S. Shrivastav, “Development of an SPE-LC-MS/MS Method for Simultaneous Quantification of Bosentan and Its Active Metabolite Hydroxybosentan in Human Plasma to Support a Bio-equivalence Study,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 70, 2012, pp. 462-470.
|
[9]
|
G. Bansal, R. Singh, B. Saini and Y. Bansal, “ESI-MS(n) and LC-ESI-MS Studies to Characterize Forced Degradation Products of Bosentan and a Validated Stability-Indicating LC-UV Method,” Journal of Pharmaceutical and Biomedical Analysis, In Press.
|
[10]
|
Center for Drug Evaluation and Research (CDER), “Q2B Validation of Analytical Procedures: Methodology,” Center for Drug Evaluation and Research.
|